Key points are not available for this paper at this time.
Cases of the steroid-resistant nephrotic syndrome that are resistant to rituximab can be difficult to treat. In this report, ofatumumab, an anti-CD20 monoclonal antibody, showed some benefit in five young patients.
Biswanath Basu (Wed,) studied this question.